Ram Mukunda - 30 Jun 2026 Form 4 Insider Report for IGC Pharma, Inc. (IGC)

Reporting relationship: CEO, Director
Issuer ticker: IGC
Reported as of: 30 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2026, 09:01:05 UTC
Prior SEC filing: 06 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Ram Mukunda

Key filing fact

Ram Mukunda filed Form 4 for IGC Pharma, Inc. (IGC) on 01 Jul 2026.

Key facts

This page summarizes Ram Mukunda's Form 4 filing for IGC Pharma, Inc. (IGC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 09:01.

Change

Previous filing in this sequence was filed on 06 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001047575 Primary reporting owner

Mukunda Ram

Relationship: CEO, Director
Address: 10224 FALLS ROAD, POTOMAC
Signature: /s/ Ram Mukunda
Signature date: 30 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IGC transaction

Common Stock

Award

Transaction value
Shares: +2,226,475
Change %: +48%
Price: $0.2700^*
Shares after: 6,875,563
Date: 30 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares of common stock acquired directly from the Issuer in a private placement in exchange for cancellation of $601,148 of outstanding indebtedness owed by the Issuer to the Reporting Person. The shares were issued at $0.27 per share, are restricted securities within the meaning of Rule 144, and were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. The transaction was approved in advance by the disinterested directors and the Audit Committee, with the Reporting Person recused, for purposes of Rule 16b-3.